Antidepressant-like effect of α-tocopherol in a mouse model of depressive-like behavior induced by TNF-α
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Taking into account that pro-inflammatory cytokines and oxidative and nitrosative stress are implicated in the pathogenesis of depression and that α-tocopherol has antidepressant, anti-inflammatory and antioxidant properties, this study investigated the ability of α-tocopherol to abolish the depressive-like behavior induced by i.c.v. administration of TNF-α in the mouse TST. Additionally, we investigated the occurrence of changes in the levels of Bcl2 and Bax and phosphorylation of GSK-3β (Ser9) in the hippocampus of mice. The administration of TNF-α (0.001fg/site, i.c.v.) increased the immobility time in the TST, which was prevented by the administration of α-tocopherol at the doses of 10, 30 and 100mg/kg (p.o.). Subeffective doses of α-tocopherol (10mg/kg, p.o.) and/or the antidepressants fluoxetine (5mg/kg, p.o.), imipramine (0.1mg/kg, p.o.) and bupropion (1mg/kg, p.o.), the NMDA receptor antagonist MK-801 (0.001mg/kg, p.o.) or the neuronal nitric oxide synthase inhibitor 7-nitroindazole (25mg/kg, i.p.) prevented the depressive-like effect induced by TNF-α. None of the treatments altered the locomotor activity of mice. Treatment with TNF-α and/or α-tocopherol did not alter the levels of Bax and Bcl2 or the phosphorylation of GSK-3β in the hippocampus of mice. Together, our results show a synergistic antidepressant-like effect of α-tocopherol with antidepressants against the depressive-like behavior induced by an inflammatory insult, suggesting that this vitamin may be useful to optimize conventional pharmacotherapy of depression, including depressive states associated with inflammatory conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Howren, M. B., Lamkin, D. M., & Suls, J. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181907c1b · Cited by 2,766
Stress-induced immune dysfunction: implications for health
Glaser, R., & Kiecolt-Glaser, J. K. (2005) · Nature Reviews Immunology · doi:10.1038/nri1571 · Cited by 2,190
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543 · cited 1×
“A consequence of the activation of NMDA receptors is the stimulation of neuronal nitric oxide synthase (nNOS), which converts L-arginine to nitric oxide (NO) and L-citrulline (Calabrese et al., 2007; Steinert et al., 2010).”
BackgroundMaes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Li, N., Liu, R.-J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.12.015 · Cited by 1,082
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Course of illness, hippocampal function, and hippocampal volume in major depression
MacQueen, G. M., Campbell, S., McEwen, B. S., Macdonald, K., Amano, S., Joffe, R. T., Nahmias, C., & Young, L. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337481100 · Cited by 980 · cited 1×
“It is important to be mentioned that decreased hippocampal volume, commonly observed in depressive patients, is closely related to reduced neurogenesis and/or increased neuronal/glial death, a scenario also observed in the presence of high levels of inflammatory cytokines (MacQueen et al., 2003; Malykhin et al., 2010).”
BackgroundCytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management
Graff, L. A., Walker, J. R., & Bernstein, C. N. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20873 · Cited by 586
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Moylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Sarandol, A., Sarandol, E., Eker, S. S., Erdinc, S., Vatansever, E., & Kirli, S. (2007) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.829 · Cited by 486
Kubera, M., Obuchowicz, E., Goehler, L., Brzeszcz, J., & Maes, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.08.026 · Cited by 443
Role of GSK3β in behavioral abnormalities induced by serotonin deficiency
Beaulieu, J.-M., Zhang, X., Rodriguiz, R. M., Sotnikova, T. D., Cools, M. J., Wetsel, W. C., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711496105 · Cited by 368
O’Brien, S. M., Scully, P., Fitzgerald, P., Scott, L. V., & Dinan, T. G. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.013 · Cited by 355
Maes, M., Fišar, Z., Medina, M., Scapagnini, G., Nowak, G., & Berk, M. (2012) · Inflammopharmacology · doi:10.1007/s10787-011-0111-7 · Cited by 325
Hayley, S., Poulter, M. O., Merali, Z., & Anisman, H. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.03.051 · Cited by 324
In Vivo Regulation of Glycogen Synthase Kinase-3β (GSK3β) by Serotonergic Activity in Mouse Brain
Li, X., Zhu, W., Roh, M.-S., Friedman, A. B., Rosborough, K., & Jope, R. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300439 · Cited by 300 · cited 1×
“…(such as fluoxetine, citalopram, desipramine, imipramine) modifies the Bax and Bcl2 levels (Bachis et al., 2008; Huang et al., 2007; Murray and Hutson, 2007) and that acute treatment with fluoxetine or imipramine altered GSK-3 phosphorylation (Li et al., 2004; Roh et al., 2005; Su et al., 2012).”
BackgroundDepressive-like behavior induced by tumor necrosis factor-α in mice
Kaster, M. P., Gadotti, V. M., Calixto, J. B., Santos, A. R. S., & Rodrigues, A. L. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.018 · Cited by 294 · cited 11×
“I.c.v. administration was performed as described by Kaster et al. (2012).”
BackgroundMethodResultInfluentialSelf-citationInflammation, Glutamate, and Glia in Depression:A Literature Review
McNally, L., Bhagwagar, Z., & Hannestad, J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016734 · Cited by 289 · cited 2×
“neurotrophic factors, glutamatergic excitotoxicity and loss of glial elements (Maes, 2008; McNally et al., 2008).”
BackgroundGlutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Behr, G. A., Moreira, J. C. F., & Frey, B. N. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/609421 · Cited by 205
In vivo antioxidant status: A putative target of antidepressant action
Zafir, A., Ara, A., & Banu, N. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.11.010 · Cited by 183
Chronic unpredictable stress promotes neuronal apoptosis in the cerebral cortex
Bachis, A., Cruz, M. I., Nosheny, R. L., & Mocchetti, I. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.081 · Cited by 138 · cited 1×
“Studies also demonstrated that chronic treatment with antidepressants (such as fluoxetine, citalopram, desipramine, imipramine) modifies the Bax and Bcl2 levels (Bachis et al., 2008; Huang et al., 2007; Murray and Hutson, 2007) and that acute treatment with fluoxetine or imipramine altered GSK-3 phosphorylation (Li et…”
BackgroundPossible connections among job stress, depressive symptoms, lipid modulation and antioxidants
Tsuboi, H., Tatsumi, A., Yamamoto, K., Kobayashi, F., Shimoi, K., & Kinae, N. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.12.010 · Cited by 119
Andrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107
Rojas, P., Serrano-García, N., Medina-Campos, O. N., Pedraza-Chaverri, J., Ögren, S. O., & Rojas, C. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.007 · Cited by 76 · cited 1×
“, 2012), Ginkgo biloba extract (Rojas et al., 2011), coenzyme Q10 (Maes et al.”
BackgroundLobato, K. R., Cardoso, C. C., Binfaré, R. W., Budni, J., Wagner, C. L. R., Brocardo, P. S., de Souza, L. F., Brocardo, C., Flesch, S., Freitas, A. E., et al. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.02.002 · Cited by 67 · cited 4×
“This result is in agreementwith the reported synergistic antidepressant-like effect in the FST elicited by the combined administration of α-tocopherol and fluoxetine (Lobato et al., 2010).”
BackgroundMethodResultInfluentialSelf-citation
Cited by
Role of the Kynurenine Metabolism Pathway in Inflammation-Induced Depression: Preclinical Approaches
Dantzer, R. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_6 · Cited by 248
“…or anti-oxidant natural compounds, such as curcumin, apigenine, honkiol, xiaobuxin-tang flavonoid extract, perillaldehyde, ginseng saponins, and alpha-tocopherol (Wang et al. 2014; Li et al. 2015a; Sulakhiya et al. 2014; An et al. 2015; Ji et al. 2014; Kang et al. 2011; Manosso et al. 2013).”
Kurosawa, N., Shimizu, K., & Seki, K. (2016) · Psychopharmacology · doi:10.1007/s00213-015-4084-x · Cited by 61
Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration
Neis, V. B., Manosso, L. M., Moretti, M., Freitas, A. E., Daufenbach, J., & Rodrigues, A. L. S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.12.038 · Cited by 59
Self-citationPatrício, P., Mateus-Pinheiro, A., Irmler, M., Alves, N. D., Machado-Santos, A. R., Morais, M., Correia, J. S., Korostynski, M., Piechota, M., Stoffel, R., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.176 · Cited by 57
Metadata
- Authors
- Manosso, L. M., Neis, V. B., Moretti, M., Daufenbach, J. F., Freitas, A. E., Colla, A. R., & Rodrigues, A. L. S.
- Venue
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 46
- Pages
- 48-57
- ISSN
- 0278-5846 (ISSN-L)
- OpenAlex
- W2086768977
- Cited by
- 68
- References
- 32
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.